GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » EV-to-EBITDA

Clearside Biomedical (Clearside Biomedical) EV-to-EBITDA

: -3.10 (As of Today)
View and export this data going back to 2016. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clearside Biomedical's enterprise value is $71.47 Mil. Clearside Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.06 Mil. Therefore, Clearside Biomedical's EV-to-EBITDA for today is -3.10.

The historical rank and industry rank for Clearside Biomedical's EV-to-EBITDA or its related term are showing as below:

CLSD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -336.91   Med: -3.24   Max: 409.08
Current: -3.1

During the past 11 years, the highest EV-to-EBITDA of Clearside Biomedical was 409.08. The lowest was -336.91. And the median was -3.24.

CLSD's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.16 vs CLSD: -3.10

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Clearside Biomedical's stock price is $1.31. Clearside Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.530. Therefore, Clearside Biomedical's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Clearside Biomedical EV-to-EBITDA Historical Data

The historical data trend for Clearside Biomedical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -3.74 [6] => -7.03 [7] => 242.74 [8] => -0.71 [9] => -1.98 )
Clearside Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.74 -7.03 242.74 -0.71 -1.98

Clearside Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -0.82 -1.26 -0.94 -1.98

Competitive Comparison

For the Biotechnology subindustry, Clearside Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's EV-to-EBITDA falls into.



Clearside Biomedical EV-to-EBITDA Calculation

Clearside Biomedical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=71.472/-23.058
=-3.10

Clearside Biomedical's current Enterprise Value is $71.47 Mil.
Clearside Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clearside Biomedical  (NAS:CLSD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Clearside Biomedical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.31/-0.530
=At Loss

Clearside Biomedical's share price for today is $1.31.
Clearside Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.530.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Clearside Biomedical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical (Clearside Biomedical) Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Executives
Charles A. Deignan officer: Chief Financial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay director 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore 10 percent owner 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp director, 10 percent owner C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla officer: Chief Medical Officer C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Daniel H. White director, officer: President and CEO C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond officer: Chief Commercial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701

Clearside Biomedical (Clearside Biomedical) Headlines

From GuruFocus